Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 748

1.

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.

Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J.

Lancet Oncol. 2019 Mar 8. pii: S1470-2045(18)30904-5. doi: 10.1016/S1470-2045(18)30904-5. [Epub ahead of print]

PMID:
30857956
2.

Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer.

Kurzrock R, Hickish T, Wyrwicz L, Saunders M, Wu Q, Stecher M, Mohanty P, Dinarello CA, Simard J.

Oncoimmunology. 2018 Dec 12;8(3):1551651. doi: 10.1080/2162402X.2018.1551651. eCollection 2019.

3.

APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy.

Boichard A, Pham TV, Yeerna H, Goodman A, Tamayo P, Lippman S, Framton GM, Tsigelny IF, Kurzrock R.

Oncoimmunology. 2018 Dec 24;8(3):1550341. doi: 10.1080/2162402X.2018.1550341. eCollection 2019.

4.

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.

Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C.

J Immunother Cancer. 2019 Feb 1;7(1):27. doi: 10.1186/s40425-019-0506-3.

6.

Novel patterns of response under immunotherapy.

Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R, Goel S, Bedard P, Le Tourneau C.

Ann Oncol. 2019 Jan 18. doi: 10.1093/annonc/mdz003. [Epub ahead of print]

PMID:
30657859
7.

Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics.

Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00183. Epub 2018 Nov 15.

8.

Identification of targets for prostate cancer immunotherapy.

Papanicolau-Sengos A, Yang Y, Pabla S, Lenzo FL, Kato S, Kurzrock R, DePietro P, Nesline M, Conroy J, Glenn S, Chatta G, Morrison C.

Prostate. 2019 Apr;79(5):498-505. doi: 10.1002/pros.23756. Epub 2019 Jan 6.

PMID:
30614027
9.

Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes.

Tray N, Taff J, Singh B, Suh J, Ngo N, Kwa M, Troxel AB, Chae YK, Kurzrock R, Patel SP, Sharon E, Denkert C, Ross JS, Adams S.

Breast. 2019 Apr;44:29-32. doi: 10.1016/j.breast.2018.12.010. Epub 2018 Dec 20.

PMID:
30609392
10.

Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials.

Galanina N, Bejar R, Choi M, Goodman A, Wieduwilt M, Mulroney C, Kim L, Yeerna H, Tamayo P, Vergilio JA, Mughal TI, Miller V, Jamieson C, Kurzrock R.

Cancers (Basel). 2018 Dec 21;11(1). pii: E11. doi: 10.3390/cancers11010011.

11.

Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.

Millis SZ, Jardim DL, Albacker L, Ross JS, Miller VA, Ali SM, Kurzrock R.

Cancer. 2019 Apr 1;125(7):1185-1199. doi: 10.1002/cncr.31921. Epub 2018 Dec 24.

PMID:
30582752
12.

Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients.

Jensen TJ, Goodman AM, Kato S, Ellison CK, Daniels GA, Kim L, Nakashe P, McCarthy E, Mazloom AR, McLennan G, Grosu DS, Ehrich M, Kurzrock R.

Mol Cancer Ther. 2019 Feb;18(2):448-458. doi: 10.1158/1535-7163.MCT-18-0535. Epub 2018 Dec 6.

PMID:
30523049
13.

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.

Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR, Hong DS.

J Immunother Cancer. 2018 Nov 16;6(1):119. doi: 10.1186/s40425-018-0436-5.

14.

ASO Author Reflections: Circulating Tumor DNA in Peritoneal Carcinomatosis.

Baumgartner JM, Kurzrock R.

Ann Surg Oncol. 2018 Dec;25(Suppl 3):772-773. doi: 10.1245/s10434-018-7029-x. Epub 2018 Nov 12. No abstract available.

PMID:
30421042
15.

An avatar for precision cancer therapy.

Kato S, Kurzrock R.

Nat Biotechnol. 2018 Nov 9;36(11):1053-1055. doi: 10.1038/nbt.4293. No abstract available.

16.

Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response.

Guram K, Nunez M, Einck J, Mell LK, Cohen E, Sanders PD, Miyauchi S, Weihe E, Kurzrock R, Boles S, Sharabi AB.

Front Oncol. 2018 Oct 17;8:435. doi: 10.3389/fonc.2018.00435. eCollection 2018.

17.

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.

Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F.

Cancer. 2019 Feb 1;125(3):463-472. doi: 10.1002/cncr.31812. Epub 2018 Nov 1.

PMID:
30383888
18.

The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match.

Subbiah V, Kurzrock R.

Oncologist. 2019 Jan;24(1):1-3. doi: 10.1634/theoncologist.2017-0519. Epub 2018 Oct 23. No abstract available.

19.

Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma.

Kato S, Okamura R, Baumgartner JM, Patel H, Leichman L, Kelly K, Sicklick JK, Fanta PT, Lippman SM, Kurzrock R.

Clin Cancer Res. 2018 Dec 15;24(24):6248-6256. doi: 10.1158/1078-0432.CCR-18-1128. Epub 2018 Oct 22.

PMID:
30348637
20.

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.

Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ.

JAMA Oncol. 2019 Jan 1;5(1):e183773. doi: 10.1001/jamaoncol.2018.3773. Epub 2019 Jan 10.

PMID:
30347019

Supplemental Content

Loading ...
Support Center